Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INVAC-1 + ibrutinib
- Development stage
- Unknown
- Lead developer
- Invectys
- Modality
- Small Molecules, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Oral
01
Overview
INVAC-1 + ibrutinib is an investigational combination regimen for the treatment of chronic lymphocytic leukemia (CLL), particularly in patients with minimal residual disease (MRD) following ibrutinib therapy[1][3]. INVAC-1 is a DNA plasmid-based therapeutic vaccine encoding a modified human telomerase reverse transcriptase (hTERT) protein. It is designed to stimulate the immune system to target cells expressing telomerase, a hallmark of many cancer cells, thereby aiding in the eradication of residual malignant cells. Ibrutinib is a small molecule Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of several B-cell malignancies, including CLL. In this combination, INVAC-1 aims to enhance immunological clearance of CLL cells, while ibrutinib suppresses B-cell receptor signaling essential for leukemic cell proliferation and survival. The combination is being evaluated in phase II clinical trials for its efficacy in achieving MRD negativity and improving long-term outcomes in CLL[1][3].
- Other names
- INVAC-1 + Imbruvica
02
Targets
TXKTERT (Telomerase)ITK (Interleukin 2-inducible T-cell kinase)BTK (Bruton tyrosine kinase)TEC (TEC proto-oncogene tyrosine-protein kinase)
Beyond the preview
Go deeper on INVAC-1 + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INVAC-1 + ibrutinib.